Erschienen in:
18.08.2017 | Case Report
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review
verfasst von:
Elda Righi, Alessia Carnelutti, Daniele Muser, Francesco Zaja, Elisa Lucchini, Federico Pea, Fernando Di Gregorio, Abass Alavi, Matteo Bassetti
Erschienen in:
Journal of NeuroVirology
|
Ausgabe 6/2017
Einloggen, um Zugang zu erhalten
Abstract
Human herpesvirus (HHV)-6 reactivation is associated with severe forms of encephalitis among patients undergoing hematopoietic stem cell transplantation. Cases in non-neutropenic patients are uncommon. The efficacy of ganciclovir and other compounds that are used for the treatment of HHV-6 encephalitis remains suboptimal and linked to toxicity. Valganciclovir, the oral prodrug of ganciclovir, could be practical to treat outpatients, but it is not commonly used for severe cases. We report a case of HHV-6 encephalitis in a non-neutropenic patient successfully treated with valganciclovir and undergoing therapeutic drug monitoring in plasma and in the cerebrospinal fluid. Resolution of infectious foci was documented by cerebral MRI and F18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). A review of the literature on HHV-6 encephalitis is also reported.